Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel

摘要

At 9%, and 2% when diagnosed at advanced stage, the 5-year relative survival rate for pancreatic ductal adenocarcinoma ( ) is the lowest of any cancer. The currently approved treatment options for metastatic in the United States are [irinotecan–fluorouracil (5 )–leucovorin ( )–oxaliplatin], gemcitabine–nab-paclitaxel, and liposomal irinotecan plus 5 – .